The role of liver biopsy in chronic hepatitis C

Hepatitis C virus (HCV) is a major cause of chronic liver disease worldwide, affecting 175 million people globally. Over 80% of acutely infected patients go on to develop chronicity, but only 20% to 25% will develop end‐stage liver disease and its complications. The sequelae of HCV‐induced chronic liver disease accounts for 8,000 to 10,000 deaths annually in the United States and is currently the leading indication for liver transplantation. To date, there are no accurate noninvasive markers of disease activity and fibrosis. Liver biopsy is indicated to exclude other forms of liver pathologies and to establish the stage of liver disease. In this study, the role of liver biopsy in chronic hepatitis C was evaluated. Additionally, we calculated a discriminant score to predict cirrhosis in chronic hepatitis C infection. Our results showed that additional diagnoses or unsuspected diagnoses are less frequent than clinicians' suspected. We confirmed that the discriminant score for predicting cirrhosis is inferior to liver biopsy. In conclusion, the majority of patients with chronic hepatitis C will require a liver biopsy, which has an important implication on staging of the liver disease, prognosis, and possibly further management options.

[1]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.

[2]  G. Davis,et al.  Therapy for chronic hepatitis C. , 1994, Gastroenterology clinics of North America.

[3]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[4]  J. Delattre,et al.  Factors associated with serum alanine transaminase activity in healthy subjects: Consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C , 1998, Hepatology.

[5]  R P Perrillo,et al.  The role of liver biopsy in hepatitis C , 1997, Hepatology.

[6]  R. W. Mccollum.  The natural history of hepatitis. , 1969, Bulletin of the New York Academy of Medicine.

[7]  T. Hügle,et al.  Hepatitis C: Update , 2001, Deutsche medizinische Wochenschrift.

[8]  Z. Younossi,et al.  Hepatitis C: an update on the silent epidemic. , 2000, Journal of clinical gastroenterology.

[9]  H. Alter.  To C or not to C: these are the questions. , 1995, Blood.

[10]  L. Seeff,et al.  Natural history of hepatitis C , 1997, Hepatology.

[11]  B. Durupınar.  [Non-A, non-B/C hepatitis]. , 1993, Mikrobiyoloji Bulteni.

[12]  Z. Younossi,et al.  The spectrum of nonalcoholic fatty liver disease: from steatosis to nonalcoholic steatohepatitis. , 2000, Cleveland Clinic journal of medicine.

[13]  M. Kojiro,et al.  Long‐term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: Morphometric analysis of repeated biopsies , 1997, Hepatology.

[14]  D. Dhumeaux,et al.  Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB/C. , 1994, Gastroenterology.

[15]  J. M. Calvo Romero,et al.  Gastric adenocarcinoma and kidney transplantation , 1998 .

[16]  D. Crowe,et al.  Liver Biopsy in the Mid-1990s: Questions and Answers , 1995, Seminars in liver disease.

[17]  K. Ishak,et al.  Histopathology of Hepatitis C Virus Infection , 1995, Seminars in liver disease.

[18]  L. Corey,et al.  Assessment of Hepatitis C Viremia Using Molecular Amplification Technologies: Correlations and Clinical Implications , 1995, Annals of Internal Medicine.

[19]  S. Govindarajan,et al.  Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. , 1997, The American journal of gastroenterology.

[20]  Inda,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.

[21]  A. Tobkes,et al.  Liver biopsy: review of methodology and complications. , 1995, Digestive diseases.

[22]  J. Ludwig,et al.  The long‐term pathological evolution of chronic hepatitis C , 1996, Hepatology.

[23]  J. Emparanza,et al.  [The prevalence of hepatitis C virus infection]. , 1998, Gastroenterologia y hepatologia.

[24]  W. Taylor,et al.  LIVER BIOPSY: COMPLICATIONS IN 1000 INPATIENTS AND OUTPATIENTS , 1978 .

[25]  M. C. Ellis,et al.  A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis , 1996, Nature Genetics.

[26]  K. Lindor,et al.  Outcome of Patients Hospitalized for Complications after Outpatient Liver Biopsy , 1993, Annals of Internal Medicine.

[27]  L. Seeff,et al.  45-Year Follow-up of Hepatitis C Virus Infection in Healthy Young Adults , 2000, Annals of Internal Medicine.

[28]  Z. Goodman,et al.  Is an “à la carte” combination interferon alfa‐2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? , 2000, Hepatology.